Patents by Inventor Joshua Courtney Horan

Joshua Courtney Horan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS
    Publication number: 20230322797
    Abstract: Provided herein are solid forms comprising a compound of formula (I), or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of synthesizing a compound of formula (I), pharmaceutical compositions comprising the same, and methods of treating, preventing, and managing various disorders using the compositions provided herein.
    Type: Application
    Filed: April 6, 2023
    Publication date: October 12, 2023
    Inventors: Christopher G. F. COOPER, Baudouin GERARD, Joshua Courtney HORAN, Jason T. KROPP, Benjamin Stephen LANE, David James PEARSON, Lauren Ashley MACEACHERN, Yameng HE, Mandeep SINGH, Arkesh NARAYANAPPA
  • Heteroaromatic macrocyclic ether chemotherapeutic agents
    Patent number: 11667649
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: November 11, 2021
    Date of Patent: June 6, 2023
    Assignee: Nuvalent, Inc.
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS
    Publication number: 20230124705
    Abstract: Provided herein are solid forms comprising a compound of formula (I), or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of synthesizing a compound of formula (I), pharmaceutical compositions comprising the same, and methods of treating, preventing, and managing various disorders using the compositions provided herein.
    Type: Application
    Filed: September 30, 2022
    Publication date: April 20, 2023
    Inventors: Sibao CHEN, Christopher G. F. COOPER, Baudouin GERARD, Joshua Courtney HORAN, Jason T. KROPP, Benjamin Stephen LANE, David James PEARSON
  • HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS
    Publication number: 20230107663
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof.
    Type: Application
    Filed: June 7, 2022
    Publication date: April 6, 2023
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS
    Publication number: 20230076627
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Application
    Filed: June 7, 2022
    Publication date: March 9, 2023
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • Heteroaromatic macrocyclic ether chemotherapeutic agents
    Patent number: 11542278
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds of Formula (I): pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: January 3, 2023
    Assignee: Nuvalent, Inc.
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS
    Publication number: 20220363696
    Abstract: Disclosed are amino-substituted heteroaromatic compounds such as 4-amino-quinazolines, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the amino-substituted heteroaromatic compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Application
    Filed: April 12, 2022
    Publication date: November 17, 2022
    Inventors: Kristin Lynne Andrews, Baudouin Gerard, Joshua Courtney Horan, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Yuting Sun, Anupong Tangpeerachaikul
  • HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS
    Publication number: 20220340586
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof Also disclosed are methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Application
    Filed: November 11, 2021
    Publication date: October 27, 2022
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS
    Publication number: 20220098212
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof Also disclosed are methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Application
    Filed: November 11, 2021
    Publication date: March 31, 2022
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • Heteroaromatic compounds as BTK inhibitors
    Patent number: 10875852
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: December 29, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joerg Bentzien, Angela Kay Berry, Todd Bosanac, Michael Jason Burke, Darren Todd Disalvo, Joshua Courtney Horan, Shuang Liang, Can Mao, Wang Mao, Yue Shen, Fariba Soleymanzadeh, Renee M. Zindell
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20190112302
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Application
    Filed: October 15, 2018
    Publication date: April 18, 2019
    Inventors: Joerg BENTZIEN, Angela Kay BERRY, Todd BOSANAC, Michael Jason BURKE, Darren Todd DISALVO, Joshua Courtney HORAN, Shuang LIANG, Can MAO, Wang MAO, Yue SHEN, Fariba SOLEYMANZADEH, Renee M. ZINDELL
  • Heteroaromatic compounds as BTK inhibitors
    Patent number: 10138229
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: November 27, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joerg Bentzien, Angela Kay Berry, Todd Bosanac, Michael Jason Burke, Darren Todd Disalvo, Joshua Courtney Horan, Shuang Liang, Can Mao, Wang Mao, Yue Shen, Fariba Soleymanzadeh, Renee M. Zindell
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20180086748
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Application
    Filed: November 16, 2017
    Publication date: March 29, 2018
    Inventors: Joerg BENTZIEN, Angela Kay BERRY, Todd BOSANAC, Michael Jason BURKE, Darren Todd DISALVO, Joshua Courtney HORAN, Shuang LIANG, Can MAO, Wang MAO, Yue SHEN, Fariba SOLEYMANZADEH, Renee M. ZINDELL
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20170320867
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 9, 2017
    Inventors: Joerg Martin BENTZIEN, Angela Kay BERRY, Todd BOSANAC, Michael Jason BURKE, Darren Todd DISALVO, Joshua Courtney HORAN, Shuang LIANG, Can MAO, Wang MAO, Yue SHEN, Fariba SOLEYMANZADEH, Renee M. ZINDELL
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20160031872
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Application
    Filed: October 16, 2015
    Publication date: February 4, 2016
    Inventors: Joerg Martin BENTZIEN, Angela Kay BERRY, Todd BOSANAC, Michael Jason BURKE, Darren Todd DISALVO, Joshua Courtney HORAN, Shuang LIANG, Can MAO, Wang MAO, Yue SHEN, Fariba SOLEYMANZADEH, Renee M. ZINDELL
  • Heteroaromatic compounds as BTK inhibitors
    Patent number: 8940893
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups X and Cy are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 27, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Todd Bosanac, Darren Disalvo, Joshua Courtney Horan, Shuang Liang, Renee M. Zindell
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20140275014
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups X and Cy are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Todd BOSANAC, Darren DISALVO, Joshua Courtney HORAN, Shuang LIANG, Renee M. ZINDELL
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20140045813
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Application
    Filed: August 8, 2013
    Publication date: February 13, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Joerg Martin BENTZIEN, Angela Kay BERRY, Todd BOSANAC, Michael Jason BURKE, Darren Todd DISALVO, Joshua Courtney HORAN, Shuang LIANG, Can MAO, Wang MAO, Yue SHEN, Fariba SOLEYMANZADEH, Renee M. ZINDELL
  • Derivatives of 6,7-dihydro-5-imidazo[1,2-]imidazole-3-carboxylic acid amides
    Patent number: 8575360
    Abstract: Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: November 5, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rene Marc Lemieux, Steven Richard Brunette, Joshua Courtney Horan, Jennifer A. Kowalski, Michael David Lawlor, Bryan McKibben, Craig Andrew Miller, Antonio J. M. Barbosa
  • Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides
    Patent number: 8552205
    Abstract: Derivatives of 6,7-dihydro-5H-imidazo[1,2-?]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: October 8, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Antonio Jose del Moral Barbosa, Jr., Joerg Martin Bentzien, Steven Richard Brunette, Zhidong Chen, Derek Cogan, Donghong A. Gao, Alexander Heim-Riether, Joshua Courtney Horan, Jennifer A. Kowalski, Michael David Lawlor, Rene Marc Lemieux, Weimin Liu, Bryan McKibben, Craig Andrew Miller, Neil Moss, Matt Aaron Tschantz, Zhaoming Xiong, Hui Yu, Yang Yu